Actively Recruiting
Real World Study of Lorlatinib for Adults With Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer
Led by Sichuan Cancer Hospital and Research Institute · Updated on 2024-04-12
200
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients with advanced or metastatic non-small cell lung cancer NSCLC that has ALK gene fusions. This observational study collects real-world data from patients treated with the third-generation ALK inhibitor lorlatinib as either a first or later line of therapy. The goal is to track disease progression, side effects, and quality of life over time to better understand treatment outcomes in this patient group. Participants receive lorlatinib orally at a dose of 100 mg once daily and continue treatment until disease progression, unacceptable side effects, withdrawal, or other clinical reasons. The study uses a multicenter approach and collects detailed clinical and treatment information from medical records. Quality of life is assessed regularly using standardized questionnaires, including measures specific to lung cancer and brain metastases. During the study, researchers gather data on tumor response, prior treatments, clinical stage, and physical condition. They monitor progression-free survival, overall survival, adverse events, and patient-reported outcomes for up to five years following the first dose. Data collection and management are supported by the REDCap platform, enabling ongoing assessment of treatment impact and safety in routine clinical practice.
CONDITIONS
Brief Title
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here